| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/JNCI/86.1.18 |
| P698 | PubMed publication ID | 7505830 |
| P2093 | author name string | Christian M | |
| Davis P | |||
| Rothenberg M | |||
| Kohn EC | |||
| Ognibene FP | |||
| Link C | |||
| Steinberg SM | |||
| Adamo DO | |||
| Bicher A | |||
| Sarosy G | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | paclitaxel | Q423762 |
| ovarian cancer | Q172341 | ||
| P304 | page(s) | 18-24 | |
| P577 | publication date | 1994-01-01 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer | |
| P478 | volume | 86 |
| Q33892907 | (-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma. |
| Q33422212 | A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies |
| Q73158685 | A phase II study of paclitaxel in platinum pretreated ovarian cancer. A Hellenic Cooperative Oncology Group study |
| Q44235595 | A phase II trial of ZD0473 in platinum-pretreated ovarian cancer. |
| Q40449536 | A preliminary risk-benefit assessment of paclitaxel. |
| Q37875412 | A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors. |
| Q33769684 | Autologous stem-cell transplantation for solid tumors in adults |
| Q40982940 | CA 125 kinetics: a cost-effective clinical tool to evaluate clinical trial outcomes in the 1990s |
| Q41689551 | Cardiovascular toxicity with cancer chemotherapy |
| Q33742794 | Chemotherapy for ovarian cancer: current concepts |
| Q33352792 | Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study |
| Q34510070 | Clinical trials and progress with paclitaxel in ovarian cancer |
| Q74296333 | Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP) |
| Q37851841 | Crude drugs as anticancer agents. |
| Q39023304 | Curcumin as a multifaceted compound against human papilloma virus infection and cervical cancers: A review of chemistry, cellular, molecular, and preclinical features |
| Q35087337 | Current therapies in ovarian cancer |
| Q33184837 | Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. |
| Q34468400 | Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines |
| Q39897412 | Dynamic monitoring of apoptosis in chemotherapies with multiple fluorescence reporters |
| Q41441798 | Gynecologic cancer in the elderly. |
| Q41056700 | High-dose chemotherapy with autologous stem cell support in advanced ovarian cancer |
| Q36114881 | Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors |
| Q33939918 | Management of gynaecological cancers |
| Q38777495 | Minimal C-terminal modification boosts peptide self-assembling ability for necroptosis of cancer cells. |
| Q40863613 | Modulation of drug resistance by alpha-tubulin in paclitaxel-resistant human lung cancer cell lines |
| Q35101318 | Ovarian epithelial-stromal interactions: role of interleukins 1 and 6. |
| Q73917900 | Overexpression of kalpha1 tubulin mRNA in thyroid anaplastic carcinoma |
| Q34660797 | Paclitaxel in cancer therapy |
| Q70937780 | Paclitaxel in the management of ovarian cancer: what we know and what we have yet to learn |
| Q33498535 | Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study |
| Q42277853 | Paclitaxel-induced neuropathy |
| Q40397088 | Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer |
| Q41757027 | Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers |
| Q34826546 | Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis |
| Q33499725 | Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer |
| Q74841396 | Phase II trial of intrapleural paclitaxel injection for non-small-cell lung cancer patients with malignant pleural effusions |
| Q41138897 | Pre-clinical activity of taxol in non-seminomatous germ cell tumor cell lines and nude mouse xenografts |
| Q54222370 | Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. |
| Q35907148 | Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system |
| Q50423643 | Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study |
| Q36694220 | Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Inst |
| Q34481727 | Recent advances in the treatment of epithelial ovarian cancer |
| Q33347044 | Results of ZD0473 in platinum-pretreated ovarian cancer: analysis according to platinum free interval. |
| Q45182288 | Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappaB and the serine/threonine kinase Akt and is independent of tubulin polymerization |
| Q36116134 | Single-agent paclitaxel in patients with previously untreated stage IV epithelial ovarian cancer. London Gynaecological Oncology and North Thames Gynaecological Oncology Groups |
| Q37570392 | Synergistic Effect of COX-2 Inhibitor on Paclitaxel-Induced Apoptosis in the Human Ovarian Cancer Cell Line OVCAR-3. |
| Q37692801 | Taxanes: their impact on gynecologic malignancy |
| Q77809158 | The clinical development of paclitaxel and the paclitaxel/carboplatin combination |
| Q48035637 | The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer |
| Q41488853 | The role of chemotherapy in the management of celomic epithelial carcinoma of the ovary |
| Q40955297 | The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors |
| Q41558368 | The transport and binding of taxol |
| Q40520314 | USA update on paclitaxel in ovarian cancer |
| Q37352629 | Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer |
Search more.